July 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals ~1 min.Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....
June 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target ~1 min.Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....
June 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit ~2 min.REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....
June 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25% ~1 min.REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....
May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit ~2 min.In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....
May 30, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target Forecast, Bringing 27.31% Profit ~1 min.On March 4, 2025, QuantWave, the automated forecasting platform, issued a short signal for REGENERON PHARMACEUTICALS, INC. stock when it was trading at $674.49....
May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits 29.73% Profit Target as Forecasted by QuantWave ~1 min.REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) achieved a significant milestone as it hit the price target forecasted by QuantWave, providing investors with a profit of 29.73%....
May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit ~1 min.QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....
May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 21.51% Profit ~1 min.REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecast set by QuantWave, resulting in a profitable outcome for investors....
May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Forecast Target with a Profit of 30.6% ~1 min.REGENERON PHARMACEUTICALS, INC. has successfully reached the price target forecasted by QuantWave, resulting in a profit of 30.6% for investors who followed the short signal....
April 12, 2025Regeneron Pharmaceuticals Receives Dupixent Approval in Japan ~1 min.Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has recently received approval for its drug Dupixent in Japan....
January 24, 2025Regeneron Pharmaceuticals, Inc. Announces Positive Results from Clinical Trial of its Breakthrough Drug ~1 min.Regeneron Pharmaceuticals, Inc., a leading biotechnology company, has recently announced positive results from a clinical trial of its groundbreaking drug....
February 3, 2025Regeneron Pharmaceuticals Inc. Receives Positive Analyst Recommendations ~1 min.Regeneron Pharmaceuticals Inc. (REGN) has recently received bullish recommendations from leading analysts, indicating a positive outlook for the company's future....
February 6, 2025Regeneron Pharmaceuticals Inc. faces legal action for Securities Law Violations - Seek advice from The Gross Law Firm ~2 min.Regeneron Pharmaceuticals Inc., a leading biotechnology company, is currently facing a lawsuit for alleged violations of securities laws....
May 30, 2025REGENERON PHARMACEUTICALS, INC. Hits Short Forecast Target with 17.43% Profit ~1 min.QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on July 1, 2022, predicted a short direction with a price of $593.76....
